A murine monoclonal antibody (MAb) with human CD4 specificity was tested for the ability to inhibit primary human immunodeficiency virus type 1 (HIV-1) isolates clades A through E. Human peripheral blood mononuclear cells (PBMC) were used as target cells for infectivity. The HIV-1 primary isolates were examined for the capacity to infect PBMC targets in the presence or absence of the anti-CD4 MAb, designated P1. P1 broadly inhibited clade A, C, D, and E isolates, based on a reduction of HIV-1 p24 antigen concentrations compared with untreated controls. Little to no virus-inhibiting activity was observed with a primary HIV-1 clade B isolate, designated BZ167. Additionally, a second primary clade B isolate was efficiently inhibited from infecting PBMC targets by P1. The data indicate that P1 exhibits group-specific inhibiting activity against non -clade B primary HIV-1 isolates in vitro. weekly coculture. Briefly, 2 1 10 6 blasts were washed in saline
In addition, vaccine candidates tested to date have failed to induce and pelleted. Cell pellets were infected with 200 mL of virus stock antibodies able to inhibit primary HIV-1 isolates across all identifor 2 h at 37ЊC with shaking every 15 min. After 2 h, the virus fied clades [2] [3] [4] , and inhibition by HIV-1-positive sera both inoculum was washed away with saline, and the infected cells within and across clades tends to be highly variable [5, 6] .
were resuspended in 2 mL of RPMI/interleukin-2 medium and HIV infection is initiated by contact between the virus envelope plated into an individual well of a 24-well tissue culture plate. On glycoprotein, gp120, and the T cell receptor, CD4. Since the initial day 4, 1 mL of the culture was removed and replaced with 1 mL binding step of all HIV isolates occurs through this gp120/CD4 of fresh medium. On day 7, 1 mL of culture was removed and interaction, antibodies specific for CD4 might be effective against replaced with 1 mL of 2 1 10 6 fresh blasts. The following HIVmultiple HIV-1 isolates. It has been shown that some anti-CD4 isolates to CD4 [7] (reviewed in [8] ). In addition, it has been in PBMC, and the stock titers ranged from 10 3 to 10 5 TCID 50 /mL.
shown that HIV-1-infected patients may be treated with antiAntigen-capture ELISA. To quantify p24 levels in our experi-CD4 MAb without any apparent deleterious effects [9] . Chimeric ments, we used a modification of an HIV-1 p24 antigen assay murine/human anti-CD4 has also been infused into patients in (Coulter, Miami) . Briefly, individual wells of 96-well microtiter milligram quantities, for weeks at a time, with no significant depleplates were coated with 50 mL of MAb anti-p24 (10 mg/mL) diluted tion of CD4-positive cells and no alteration of the phenotype of in borate-buffered saline (BBS) for 1 h at 37ЊC. The unbound sites peripheral blood lymphocytes [10] . In this set of experiments, we were blocked by addition of 200 mL of 5% goat serum diluted in used a murine anti-CD4 MAb, designated P1, to test neutralization BBS (GSBBS) for 30 min at 37ЊC. The wells were then washed of various HIV-1 primary isolates across clades.
five times with BBS containing 0.05% Tween 20 (BBST). Samples (50 mL) were loaded and incubated for 1 h at 37ЊC and washed Materials and Methods five times with BBST. The anti-p24 biotin reagent from the kit was then diluted 1:4 in GSBBS, and 50-mL volumes were added Virus stocks. HIV-1 primary isolates were obtained from Qualto the wells for 1 h at 37ЊC. Unbound material was washed away ity Biologicals (Gaithersburg, MD), the Aaron Diamond AIDS with five washes with BBST. Finally, 50 mL of a predetermined dilution of streptavidin-horseradish peroxidase diluted in GSBBS was added for 30 min at 37ЊC. Unbound streptavidin-horseradish 1.40. This corresponded with an HIV-1 p24 concentration of 10-600 ng/mL as determined from the linear portion of the standard curve (data not shown). TCID 50 determination. HIV-1 stocks were serially diluted (1:10) in saline, and 2 1 10 6 PBMC blasts were infected for 2 h at 37ЊC. The virus inoculum was washed away with saline, and the cells were resuspended in 1 mL of medium. The cells were then aliquoted into 10 wells of a 96-well tissue culture plate (100 mL/well). On day 4, 100 mL of fresh medium was added, and on day 7, the wells were tested for p24. The TCID 50 /mL was determined by the Reed-Muench method.
Cell viability assay. To evaluate the viability of our PBMC preparations, we used MTT as an indicator of metabolic activity. Briefly, samples of cells from our neutralization experiments were harvested, and 0.1 vol of MTT (5 mg/mL) in RPMI was added for 4 h at 37ЊC. Converted dye was then solubilized with an equal volume of 1 M HCl and vigorous pipetting. The assay was measured spectrophotometrically on an ELISA plate reader at 570 nm.
MAb P1. P1 is a murine MAb generated by the fusion of SP2/0 myeloma cells with BALB/c immune splenocytes. P1 is an Figure 1 . Kinetics of HIV-1 primary isolate replication in human IgG1/k, was produced as an ascitic tumor, and was subsequently PBMC. Antigen-capture ELISA was used to estimate HIV-1 p24 purified on protein A-sepharose by standard procedures. P1 has levels in infected PBMC; 100 (), 10 (l), and 1 (᭡) TCID 50 /mL been shown to be identical to Leu-3a in epitope specificity. In inocula were tested to examine kinetics of viral replication over 10-addition, P1 varies by only 2 conserved amino acids in the heavyday period and determine dose for neutralization experiments. chain variable region and is identical in light-chain variable region amino sequence to Leu-3a [11] .
Neutralization assay. Fresh 3 day-blasted human PBMC, formed similar studies with the other HIV-1 isolates (data not 2 1 10 6 /experiment, were harvested and washed two times in shown) and also found 100 TCID 50 /mL to be optimal.
saline. Cells were pretreated or not with the anti-CD4 MAb, P1,
Effect of P1 on PBMC viability. Before testing for inhibior isotype-matched control MAb and pelleted before infection for
tion, it was necessary to test whether P1 itself had any toxic 2 h at 37ЊC with 200 mL of HIV stock in medium. Infected cells effect on the PBMC blasts. To evaluate toxicity, we used the were shaken every 15 min during the 2-h infection, after which MTT cell viability assay. No significant decrease in viability the PBMC were pelleted, and unadsorbed virus was washed away was observed in the presence of P1 at 10 and 100 mg/mL (data with saline. Finally, the infected cells were resuspended in 2 mL not shown). The results indicate that P1 is not toxic to the of RPMI/interleukin-2 medium and added to individual wells of 24-well tissue culture plates. Cells were fed on days 4, 7, and 10 PBMC blasts that will serve as targets for subsequent infectivity by removing 1 mL of culture and replacing it with 1 mL of fresh assays.
medium. The level of infectivity was determined on the basis of
Inhibition of HIV-1 primary isolates by MAb anti-CD4.
optical density values from the HIV-1 p24 ELISA.
Levels of HIV-1 p24 in cultures of human PBMC infected with representative primary isolates in the presence or absence of anti-CD4 MAb P1 are shown in table 1. On days 4, 7, and 10, the clade A isolate was inhibited with 10 mg/mL by 91%, Results 7%, and 0, and with 100 mg/mL by 91%, 100%, and 98%, respectively. Clade B (BZ167) was inhibited with 10 mg/mL Kinetics of viral replication. Before examining the ability of P1 to inhibit the various primary isolate clades, it was necesby 54%, 0, and 0, and with 100 mg/mL by 91%, 15%, and 12%, respectively. The clade C isolate was inhibited with 10 sary to determine the kinetics of HIV-1 replication in human PBMC. We infected phytohemagglutinin-blasted PBMC as demg/mL by 76%, 97%, and 91%, and with 100 mg/mL by 84%, 95%, and 98%. Similarly, 10 mg/mL decreased clade D by scribed above. Inocula of 1, 10, and 100 TCID 50 /mL were tested. Samples were taken at days 4, 7, and 10 and assayed 100%, 93%, and 90%, and 100 mg/mL by 100%, 100%, and 100%, respectively. The clade E isolate was inhibited by 91%, by p24 antigen capture. In figure 1 , the kinetics of HIV-1 (UG001) replication are depicted. On the basis of HIV-1 p24 99%, and 98% and by 90%, 98%, and 98% with 10 mg/mL and 100 mg/mL, respectively. In replicate cultures that conlevels, at 100 TCID 50 /mL inoculum, virus titers are maximum and constant from days 4, 7, and 10. At 10 TCID 50 /mL, tained the same concentrations of a control MAb specific for hepatitis B surface antigen, inhibition of HIV-1 infectivity was the virus titers steadily increase from day 4 to day 10. At 1 TCID 50 /mL, the titers are not sufficient even at day 10. For õ15%. To address the issue regarding the lack of efficient inhibitory activity against the clade B isolate, we examined evaluating the inhibitory activity of the anti-CD4, a 100 TCID 50 /mL inoculum was selected for further studies. We pera second clade B isolate, along with other primary isolates / 9d46$$ju46 05-11-98 10:41:02 jinfa UC: J Infect representing the other clades. P1 efficiently inhibited the second B primary isolates. These data suggest that BZ167 may infect PBMC without the need for a CD4 interaction or may interact clade B isolate (A284), similar to the levels of inhibition observed with the representative clade A, C, D, and E isolates with a CD4 epitope not recognized by P1 and different from the CD4 epitope used by the other primary isolates of HIV-1. (data not shown).
